[go: up one dir, main page]

MX2009008022A - Metodos y composiciones para tratar neuropatias. - Google Patents

Metodos y composiciones para tratar neuropatias.

Info

Publication number
MX2009008022A
MX2009008022A MX2009008022A MX2009008022A MX2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A MX 2009008022 A MX2009008022 A MX 2009008022A
Authority
MX
Mexico
Prior art keywords
methods
activity
treating
neuropathies
compositions
Prior art date
Application number
MX2009008022A
Other languages
English (en)
Inventor
Jeffrey Milbrandt
Biplab Dasgupta
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2009008022A publication Critical patent/MX2009008022A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen métodos para tratar o prevenir la degradación axonal en enfermedades neuropáticas y trastornos neurológicos en mamíferos; los métodos pueden comprender administrar al mamífero una cantidad efectiva de un agente que actúa, por lo menos en parte, aumentando la actividad sirtuinAMPK, la actividad LKB 1 y/o la actividad CaMKKß en neuronas enfermas y/o lesionadas; los métodos también pueden comprender administrar al mamífero una cantidad efectiva de un agente que actúa aumentando la cavidad de NAD en neuronas enfermas y/o lesionadas, solo o en combinación con agentes que actúan por otros mecanismos; también se describen métodos para analizar agentes para el tratamiento de neuropatías y vectores recombinantes para el tratamiento o la prevención de dichas neuropatías.
MX2009008022A 2007-01-26 2008-01-28 Metodos y composiciones para tratar neuropatias. MX2009008022A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88685407P 2007-01-26 2007-01-26
PCT/US2008/001085 WO2008091710A2 (en) 2007-01-26 2008-01-28 Methods and compositions for treating neuropathies

Publications (1)

Publication Number Publication Date
MX2009008022A true MX2009008022A (es) 2009-12-11

Family

ID=39645095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008022A MX2009008022A (es) 2007-01-26 2008-01-28 Metodos y composiciones para tratar neuropatias.

Country Status (5)

Country Link
US (3) US20100047177A1 (es)
EP (1) EP2124985A4 (es)
CA (1) CA2676609A1 (es)
MX (1) MX2009008022A (es)
WO (1) WO2008091710A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108999A1 (en) 2008-03-03 2009-09-11 Ross Stewart Grant Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
CN102143744B (zh) * 2008-07-25 2016-08-31 爱默蕾大学 7,8-二羟基黄酮及其衍生物在制备治疗抑郁的药物中的用途
CA2746506A1 (en) 2008-12-08 2010-07-08 Northwestern University Method of modulating hsf-1
JP2010215563A (ja) * 2009-03-17 2010-09-30 Kao Corp Ｌｋｂ１活性化剤
CA2801415A1 (en) 2010-06-09 2011-12-15 Emory University Trkb agonists and methods of use
CN102305863B (zh) * 2011-07-18 2013-11-20 厦门大学 以Nur77-LKB1相互作用为靶点的抗糖尿病药物筛选方法
WO2014018741A1 (en) 2012-07-27 2014-01-30 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
EP4233878B1 (en) 2013-03-15 2025-05-07 Washington University Administration of nicotinamide mononucleotide in the treatment of photoreceptor degeneration or damage
CN103877076B (zh) * 2014-03-21 2016-06-29 景临林 5,6,7,8-四羟基黄酮在制备抗缺氧药物中的应用
CA2951287A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
EP3670522B1 (en) 2014-07-24 2022-01-19 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside chloride
CA2978069C (en) 2015-03-09 2021-10-12 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
US20170068860A1 (en) * 2015-09-09 2017-03-09 Alex Adekola System for measuring crowd density
GB2542881B (en) * 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
WO2017201425A1 (en) * 2016-05-20 2017-11-23 The Trustees Columbia University In The City Of New York Anabolic enhancers for ameliorating neurodegeneration
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
WO2019126482A1 (en) 2017-12-22 2019-06-27 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
US12117453B2 (en) 2018-12-07 2024-10-15 Washington University Predicting patient response to sodium channel blockers
JP7473565B2 (ja) 2019-01-28 2024-04-23 ミトコンドリア エモーション， インク． マイトフュージン活性化物質及びその使用方法
EP3917509A4 (en) 2019-01-28 2022-11-09 Mitochondria Emotion, Inc. ACTIVATORS OF TRANS-4-HYDROXYCYCLOHEXYLPHENYLAMIDE DERIVATIVES OF MITOFUSIN AND METHODS OF USE THEREOF
IT202000007726A1 (it) * 2020-04-10 2021-10-10 Solongevity Nutraceuticals S R L Composizioni mimetiche della restrizione calorica
CN114259486B (zh) * 2020-09-16 2024-04-02 香港科技大学 木犀草素及其药物组合物的应用
AU2022226257A1 (en) * 2021-02-26 2023-09-07 Icahn School Of Medicine At Mount Sinai Method for decreasing degeneration of retinal ganglion cells
CN115212165B (zh) * 2022-08-19 2024-12-03 哈尔滨医科大学 修复神经热损伤的凝胶及其制备方法和应用
EP4338798A1 (en) 2022-09-16 2024-03-20 Wasilewicz, Robert Henryk Pharmaceutical preparation containing genistein for use in the prevention or treatment of glaucoma and/or ocular hypertension
WO2024170772A1 (en) * 2023-02-17 2024-08-22 Mim Neurosciences Ab Epigallocatechin-3-gallate (egcg) analogs for use in the treatment of diseases in which an increase of nad+ is beneficial such as glaucoma
CN116869991A (zh) * 2023-06-06 2023-10-13 南昌大学 柚皮素在制备治疗和/或预防眼部疾病的药物中的用途
KR20250056047A (ko) 2023-10-18 2025-04-25 성균관대학교산학협력단 알피넘아이소플라본을 포함하는 자궁내막증 예방 또는 치료용 약제학적 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055845A1 (en) * 1998-04-28 1999-11-04 Mitokor Cellular and animal models for diseases associated with altered mitochondrial function
US6001368A (en) * 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
IT1302365B1 (it) * 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
EP1181374A4 (en) * 1999-05-28 2003-04-23 Immunex Corp NEW HUMAN AND MURINE KINASES
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
AU2003268235A1 (en) * 2002-09-09 2004-03-29 Mitochroma Research, Inc. Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation
GB2402938B (en) * 2003-06-17 2005-11-09 Medical Res Council Kinase assay
EP2289504A3 (en) * 2003-07-01 2012-05-23 President and Fellows of Harvard College SIRT1 modulators for manipulating cell/organism lifespan/stress response
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005004814A2 (en) * 2003-07-02 2005-01-20 Elixir Pharmaceuticals, Inc. Sirt1 and genetic disorders
JP2007527418A (ja) * 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肥満及びインシュリン耐性障害を治療又は防止するための組成物
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050227327A1 (en) * 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
WO2005077091A2 (en) * 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
CA2567848A1 (en) * 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
US20060035302A1 (en) * 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
US20070244202A1 (en) * 2004-06-28 2007-10-18 Kao Corporation Ampk Activator
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
PT1910384E (pt) * 2005-08-04 2013-01-23 Sirtris Pharmaceuticals Inc Derivados de imidazo[2,1-b]tiazole como compostos moduladores da sirtuína
NZ578891A (en) * 2007-01-16 2012-03-30 Ipintl Llc Novel composition for treating metabolic syndrome

Also Published As

Publication number Publication date
CA2676609A1 (en) 2008-07-31
WO2008091710A3 (en) 2008-10-09
US20160367497A1 (en) 2016-12-22
US20140011890A1 (en) 2014-01-09
WO2008091710A2 (en) 2008-07-31
US20100047177A1 (en) 2010-02-25
EP2124985A2 (en) 2009-12-02
EP2124985A4 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
MX2009008022A (es) Metodos y composiciones para tratar neuropatias.
WO2006001982A3 (en) Methods and compositions for treating neuropathies
MY176679A (en) Use of nutritional compositions for preventing disorders
WO2007028085A3 (en) Neuregulin for prevention and treatment of damage from acute assault on vascular and neuronal tissues
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MY151018A (en) Use of nutritional compositions for preventing disorders
HRP20130707T1 (en) Compositions and uses for treating multiple sclerosis
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
WO2005000331A3 (en) Compositions for the treatment and prevention of degenerative joint disorders
UA85055C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2010003548A (es) Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida.
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
TW200740804A (en) Glucokinase activators
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
EP3150635A3 (en) Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
WO2006105315A3 (en) Compositions and methods for regulating inflammatory responses
WO2007040565A3 (en) Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
WO2006078574A3 (en) Mitotic kinesin inhibitors
MX2009006768A (es) Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes.
PL1979521T3 (pl) Nowy sposób impregnowania powierzchni tekstylnych
WO2007123848A3 (en) Therapeutic compositions containing modified class i slrp proteins
ZA202106809B (en) Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
WO2007117558A3 (en) Antioxidants and methods of their use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal